financetom
Business
financetom
/
Business
/
SoftBank seen returning to loss in Q4 despite tech stock strength
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SoftBank seen returning to loss in Q4 despite tech stock strength
May 9, 2024 10:54 PM

TOKYO (Reuters) - Japanese technology investor SoftBank Group is expected to slip back into the red when it reports earnings on Monday despite technology stocks including Arm Holdings, its core asset, performing well over the quarter.

Analysts and investors are also eagerly awaiting clues about new growth investments as SoftBank has ample liquidity and can monetise its huge holding in Arm.

The share price of Britain-based Arm, in which SoftBank has a 90% stake, roughly doubled in February after strong earnings results stoked investor excitement over Arm's anticipated gains from the adoption of generative artificial intelligence (AI), but Arm's share price does not feed into SoftBank's profit as it is a wholly-owned subsidiary.

The performance of SoftBank's other listed assets were mixed over the quarter - shares in Coupang and DoorDash rose but DiDi Global and Grab Holdings fell. The initial public offering (IPO) market remained subdued, leaving analysts uncertain of the monetisation prospects for SoftBank's portfolio of unlisted tech startups.

SoftBank is slated to record a net loss of 72 billion yen ($462.70 million) over January-March, according to the average of two analysts polled by LSEG, compared to a 985 billion yen net profit in the previous three months.

SoftBank's management has said it is ready to make new growth investments but has stressed it will adopt a cautious approach.

New investments were minimal in the October-December quarter but analysts say a large, controlling acquisition - along the lines of its $32 billion purchase of Arm in 2016 - could be in the offing.

SoftBank could fund up to $30 billion by combining its liquidity at hand as of the end of 2023, the proceeds of bonds issued in March and by negotiating a margin loan on its Arm stake, according to calculations by Nomura Securities credit analyst Shogo Tono.

But while the Arm stake may make possible an investment on this scale, its dominance within SoftBank's portfolio poses a risk should market sentiment turn, hitting SoftBank's value and fundraising capacity.

Currently Arm trades at premium valuations far in excess of competitors such as Nvidia that have pushed it to constitute almost half of SoftBank's equity value.

Some analysts warn this is unsustainable. Moningstar analyst Javier Correonero estimates a fair value for Arm of $57 per share, compared to its recent trading range around $100 per share.

Investors were disappointed by Arm's annual revenue forecast at its quarterly earnings on Wednesday, sending its shares tumbling up to 8.5% the following day and underlining the risk of a major rerating.

($1 = 155.6100 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Decliners
Top Premarket Decliners
Oct 10, 2024
07:50 AM EDT, 10/08/2024 (MT Newswires) -- ZJK Industrial ( ZJK ) shares slumped 25% pre-bell Tuesday, reversing Monday's surge. SOBR Safe ( SOBR ) shares dropped 22% after the company priced an $8.2 million private placement of units. QuantaSing Group ( QSG ) shares fell 19%, erasing gains from the previous session. Luokung Technology ( LKCO ) shares retreated...
Market Chatter: Pfizer's Former Executives Pitch Starboard's Turnaround Plans to Board
Market Chatter: Pfizer's Former Executives Pitch Starboard's Turnaround Plans to Board
Oct 10, 2024
07:46 AM EDT, 10/08/2024 (MT Newswires) -- Pfizer's ( PFE ) former top executives have pitched activist investor Starboard Value's plans to Chief Executive Albert Bourla and at least three other directors, Financial Times reported Tuesday, citing people familiar with the matter. Former chair and CEO Ian Read and former finance chief Frank D'Amelio, who have been advising Starboard, spoke...
Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says
Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says
Oct 10, 2024
07:53 AM EDT, 10/08/2024 (MT Newswires) -- Scholar Rock's ( SRRK ) shares pulled back early Tuesday after more than quadrupling a day earlier on upbeat data from a drug that Truist Securities said could result in earlier treatment for patients with spinal muscular atrophy. Investors were taking some profit pre-bell after the shares surged 362% by the close Monday,...
KKR Buys The Parking Spot
KKR Buys The Parking Spot
Oct 10, 2024
07:49 AM EDT, 10/08/2024 (MT Newswires) -- KKR (KKR) said Tuesday it has bought near-airport parking properties owner The Parking Spot from Green Courte Partners. Financial terms were not disclosed, the company said. Price: 130.80, Change: -0.53, Percent Change: -0.40 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved